肾移植缺血再灌注后sFlt-1升高与不良临床结局相关
该纵向研究纳入93例肾移植受者并结合多种动物模型,评估缺血再灌注后血清可溶性fms样酪氨酸激酶1(sFlt-1)升高与肾微血管功能障碍的因果关系。结果显示sFlt-1较高者移植物功能延迟恢复、排斥、移植物功能受损及死亡风险更高,动物实验证实sFlt-1可致肾微血管结构与功能改变,中和sFlt-1可保护管周毛细血管并减轻纤维化。
要点
- 肾移植后早期sFlt-1升高与移植物功能延迟恢复、排斥及死亡风险增加相关
- sFlt-1升高者管周毛细血管面积更低,提示微血管功能障碍
- 动物模型中中和sFlt-1可保留管周毛细血管密度并减轻肾纤维化
核心结论
- 肾移植缺血再灌注后高sFlt-1水平参与微血管功能障碍的发病机制,进而导致不良临床结局。
研究设计与样本
- 纵向研究纳入93例肾移植受者,并结合多种动物模型评估sFlt-1与肾微血管功能障碍的因果关系。
主要发现
- sFlt-1水平较高的受者移植物功能延迟恢复、移植物排斥、移植物功能受损和死亡的几率更高。
- 25例受者移植后4个月内行肾活检,血清sFlt-1升高者管周毛细血管面积更低。
- 给啮齿类动物注射重组sFlt-1可致管周毛细血管密度和毛细血管内血容量降低,并增加炎症基因表达和纤维化。
- 在小鼠缺血再灌注模型中肾脏是sFlt-1产生部位,全身中和sFlt-1可保留管周毛细血管密度并减轻肾纤维化。
临床怎么用
- 肾移植后早期监测血清sFlt-1可能有助于识别微血管功能障碍和不良结局高风险受者。
- sFlt-1中和策略在动物模型中显示保护作用,尚需临床研究验证其转化价值。
局限性
- 研究为纵向观察设计,人体部分样本量有限,sFlt-1与结局的因果关系主要依赖动物模型支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Renal ischemia reperfusion injury (IRI) adversely affects clinical outcomes following kidney transplantation. Understanding the cellular mechanisms and the changes in gene/protein expression following IRI may help to improve these outcomes. Serum soluble fms-like tyrosine kinase 1 (sFlt-1), a circulating antiangiogenic protein, is increased in the first week following kidney transplantation. We evaluated the casual relationship of elevated sFlt-1 levels with renal microvascular dysfunction following IRI in a longitudinal study of 93 kidney transplant recipients and in several animal models. Transplant recipients with higher sFlt-1 levels had higher odds of delayed graft function, graft rejection, impaired graft function, and death. In a subgroup of 25 participants who underwent kidney biopsy within 4 months of kidney transplantation, peritubular capillary area was lower in those with elevated serum sFtl-1 levels. The administration of recombinant sFlt-1 into rodents resulted in significant structural and functional changes of the renal microvasculature, including reduced peritubular capillary density and intracapillary blood volume, and lead to increased expression of inflammatory genes and increased fibrosis. In a murine model of IRI, the kidney was a site of sFlt-1 production, and systemic neutralization of sFlt-1 preserved peritubular capillary density and alleviated renal fibrosis. Our data indicate that high sFlt-1 levels after IRI play an important role in the pathogenesis of microvascular dysfunction, thereby contributing to adverse clinical outcomes following kidney transplantation.
引用
- Wewers TM, Mayer AB, Pfleiderer A, et al. Increased soluble fms-like tyrosine kinase 1 after ischemia reperfusion contributes to adverse clinical outcomes following kidney transplantation. Kidney Int. 2019. PMID: 30824181. doi:10.1016/j.kint.2018.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。